KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Liabilities (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Total Liabilities data on record, last reported at $71.3 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 98.02% year-over-year to $71.3 million; the TTM value through Dec 2025 reached $71.3 million, down 98.02%, while the annual FY2025 figure was $71.3 million, 98.02% down from the prior year.
  • Total Liabilities reached $71.3 million in Q4 2025 per AMRX's latest filing, down from $110.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $3.7 billion in Q3 2022 and bottomed at -$407.4 million in Q1 2022.
  • Average Total Liabilities over 5 years is $1.8 billion, with a median of $1.8 billion recorded in 2023.
  • Peak YoY movement for Total Liabilities: crashed 111.34% in 2022, then soared 2404.61% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $3.6 billion in 2021, then rose by 1.19% to $3.6 billion in 2022, then dropped by 4.5% to $3.5 billion in 2023, then grew by 4.58% to $3.6 billion in 2024, then plummeted by 98.02% to $71.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $71.3 million in Q4 2025, $110.0 million in Q3 2025, and $112.5 million in Q2 2025.